HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines

Lorena Landuzzi, Agnese Antognoli, Giordano Nicoletti, Stefania Croci, Arianna Palladini, Marianna Lucia Ianzano, Annalisa Murgo, Valeria Stivani, Valentina Grosso, Patrizia Nanni, Carla De Giovanni, Pier Luigi Lollini

Research output: Contribution to journalArticle

Abstract

Main obstacles to cancer vaccine efficacy are pre-existing antigenic load and immunoescape mechanisms, including tolerance against self tumor-associated antigens. Here we explored the role of tolerance in an antimetastatic vaccine approach based on dendritic cell-tumor cell (DC-TC) hybrids, thanks to the comparison between BALB-neuT mice, transgenic for and tolerant to rat HER-2/neu, with their nontolerant strain of origin BALB/c. Allogeneic DC-TC hybrid vaccine displayed a high antimetastatic activity in non-tolerant mice, but was far less effective in tolerant mice, even with intensified vaccine schedule. Tolerant BALB-neuT mice revealed a reduced ability to mount polarized Th1 responses. A further attempt to increase the antimetastatic activity by using LPS-matured DC hybrids failed. Allogeneic LPS-matured DC-TC hybrids induced high IFN-γ levels, but concomitantly also the highest production of IL-4 and IL-10 suggesting activation of mechanisms sustaining regulatory cells able to blunt vaccine efficacy. Our data in tolerant versus non-tolerant hosts suggest that clinical translation of effective DC-based strategies could benefit from more extensive investigations in tolerant transgenic models.

Original languageEnglish
Pages (from-to)4690-4697
Number of pages8
JournalVaccine
Volume29
Issue number29-30
DOIs
Publication statusPublished - Jun 24 2011

Fingerprint

Hybrid Cells
dendritic cells
Dendritic Cells
Vaccines
vaccines
mice
Neoplasms
Cancer Vaccines
genetically modified organisms
Neoplasm Antigens
neoplasms
Interleukin-4
Interleukin-10
Transgenic Mice
interleukin-4
Appointments and Schedules
interleukin-10
translation (genetics)
neoplasm cells
antigens

Keywords

  • Cancer vaccines
  • Dendritic cells
  • HER-2/neu
  • Metastasis
  • Transgenic mice

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. / Landuzzi, Lorena; Antognoli, Agnese; Nicoletti, Giordano; Croci, Stefania; Palladini, Arianna; Ianzano, Marianna Lucia; Murgo, Annalisa; Stivani, Valeria; Grosso, Valentina; Nanni, Patrizia; De Giovanni, Carla; Lollini, Pier Luigi.

In: Vaccine, Vol. 29, No. 29-30, 24.06.2011, p. 4690-4697.

Research output: Contribution to journalArticle

Landuzzi, L, Antognoli, A, Nicoletti, G, Croci, S, Palladini, A, Ianzano, ML, Murgo, A, Stivani, V, Grosso, V, Nanni, P, De Giovanni, C & Lollini, PL 2011, 'HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines', Vaccine, vol. 29, no. 29-30, pp. 4690-4697. https://doi.org/10.1016/j.vaccine.2011.04.096
Landuzzi, Lorena ; Antognoli, Agnese ; Nicoletti, Giordano ; Croci, Stefania ; Palladini, Arianna ; Ianzano, Marianna Lucia ; Murgo, Annalisa ; Stivani, Valeria ; Grosso, Valentina ; Nanni, Patrizia ; De Giovanni, Carla ; Lollini, Pier Luigi. / HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. In: Vaccine. 2011 ; Vol. 29, No. 29-30. pp. 4690-4697.
@article{25b5db0c4965492ebf6063b16b151d3a,
title = "HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines",
abstract = "Main obstacles to cancer vaccine efficacy are pre-existing antigenic load and immunoescape mechanisms, including tolerance against self tumor-associated antigens. Here we explored the role of tolerance in an antimetastatic vaccine approach based on dendritic cell-tumor cell (DC-TC) hybrids, thanks to the comparison between BALB-neuT mice, transgenic for and tolerant to rat HER-2/neu, with their nontolerant strain of origin BALB/c. Allogeneic DC-TC hybrid vaccine displayed a high antimetastatic activity in non-tolerant mice, but was far less effective in tolerant mice, even with intensified vaccine schedule. Tolerant BALB-neuT mice revealed a reduced ability to mount polarized Th1 responses. A further attempt to increase the antimetastatic activity by using LPS-matured DC hybrids failed. Allogeneic LPS-matured DC-TC hybrids induced high IFN-γ levels, but concomitantly also the highest production of IL-4 and IL-10 suggesting activation of mechanisms sustaining regulatory cells able to blunt vaccine efficacy. Our data in tolerant versus non-tolerant hosts suggest that clinical translation of effective DC-based strategies could benefit from more extensive investigations in tolerant transgenic models.",
keywords = "Cancer vaccines, Dendritic cells, HER-2/neu, Metastasis, Transgenic mice",
author = "Lorena Landuzzi and Agnese Antognoli and Giordano Nicoletti and Stefania Croci and Arianna Palladini and Ianzano, {Marianna Lucia} and Annalisa Murgo and Valeria Stivani and Valentina Grosso and Patrizia Nanni and {De Giovanni}, Carla and Lollini, {Pier Luigi}",
year = "2011",
month = "6",
day = "24",
doi = "10.1016/j.vaccine.2011.04.096",
language = "English",
volume = "29",
pages = "4690--4697",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "29-30",

}

TY - JOUR

T1 - HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines

AU - Landuzzi, Lorena

AU - Antognoli, Agnese

AU - Nicoletti, Giordano

AU - Croci, Stefania

AU - Palladini, Arianna

AU - Ianzano, Marianna Lucia

AU - Murgo, Annalisa

AU - Stivani, Valeria

AU - Grosso, Valentina

AU - Nanni, Patrizia

AU - De Giovanni, Carla

AU - Lollini, Pier Luigi

PY - 2011/6/24

Y1 - 2011/6/24

N2 - Main obstacles to cancer vaccine efficacy are pre-existing antigenic load and immunoescape mechanisms, including tolerance against self tumor-associated antigens. Here we explored the role of tolerance in an antimetastatic vaccine approach based on dendritic cell-tumor cell (DC-TC) hybrids, thanks to the comparison between BALB-neuT mice, transgenic for and tolerant to rat HER-2/neu, with their nontolerant strain of origin BALB/c. Allogeneic DC-TC hybrid vaccine displayed a high antimetastatic activity in non-tolerant mice, but was far less effective in tolerant mice, even with intensified vaccine schedule. Tolerant BALB-neuT mice revealed a reduced ability to mount polarized Th1 responses. A further attempt to increase the antimetastatic activity by using LPS-matured DC hybrids failed. Allogeneic LPS-matured DC-TC hybrids induced high IFN-γ levels, but concomitantly also the highest production of IL-4 and IL-10 suggesting activation of mechanisms sustaining regulatory cells able to blunt vaccine efficacy. Our data in tolerant versus non-tolerant hosts suggest that clinical translation of effective DC-based strategies could benefit from more extensive investigations in tolerant transgenic models.

AB - Main obstacles to cancer vaccine efficacy are pre-existing antigenic load and immunoescape mechanisms, including tolerance against self tumor-associated antigens. Here we explored the role of tolerance in an antimetastatic vaccine approach based on dendritic cell-tumor cell (DC-TC) hybrids, thanks to the comparison between BALB-neuT mice, transgenic for and tolerant to rat HER-2/neu, with their nontolerant strain of origin BALB/c. Allogeneic DC-TC hybrid vaccine displayed a high antimetastatic activity in non-tolerant mice, but was far less effective in tolerant mice, even with intensified vaccine schedule. Tolerant BALB-neuT mice revealed a reduced ability to mount polarized Th1 responses. A further attempt to increase the antimetastatic activity by using LPS-matured DC hybrids failed. Allogeneic LPS-matured DC-TC hybrids induced high IFN-γ levels, but concomitantly also the highest production of IL-4 and IL-10 suggesting activation of mechanisms sustaining regulatory cells able to blunt vaccine efficacy. Our data in tolerant versus non-tolerant hosts suggest that clinical translation of effective DC-based strategies could benefit from more extensive investigations in tolerant transgenic models.

KW - Cancer vaccines

KW - Dendritic cells

KW - HER-2/neu

KW - Metastasis

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=79960637991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960637991&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.04.096

DO - 10.1016/j.vaccine.2011.04.096

M3 - Article

C2 - 21569812

AN - SCOPUS:79960637991

VL - 29

SP - 4690

EP - 4697

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 29-30

ER -